Better Health for All

Incyte Corporation's core business focuses on the discovery, development, and commercialization of novel medicines for serious unmet medical needs in oncology, inflammation, and autoimmunity, indicating that the majority of its product portfolio delivers significant health benefits. The company does not generate revenue from products with established negative health outcomes. Incyte offers comprehensive patient assistance programs, such as IncyteCARES, which provide free medication to eligible uninsured or underinsured patients for products like Jakafi, PEMAZYRE, and ZYNYZ.

These programs are valued at an estimated $50-75 million annually. When compared to Jakafi's annual revenues of $2.16 billion in 2022, this represents approximately 2.31% to 3.47% of that revenue.

Fair Money & Economic Opportunity

Incyte Corporation is a biopharmaceutical company, and the 'Fair Money & Economic Opportunity' value primarily assesses financial institutions. Most KPIs in this rubric are designed for companies offering lending, insurance, or other financial services. As Incyte does not provide such services, KPIs including pricing_fairness, exploitative_fee_exposure, inclusion_initiatives, data_accessibility, fair_lending_compliance, wealth_building_outcome, profit_reinvestment, financial_literacy_initiatives, debt_burden_ratio, geographic_inclusion, and product_simplicity are scored 0, indicating they are not applicable to the company's core business. While Incyte offers patient assistance programs based on income

, the provided articles do not specify the percentage of total customers from underserved segments, which is required for scoring the underserved_client_share KPI. Therefore, this KPI is omitted due to a lack of specific quantitative evidence. Evidence regarding drug pricing , , discounts , local economic investment , and a False Claims Act settlement does not align with the specific financial service criteria of the rubric.

Fair Pay & Worker Respect

In 2023, Incyte's CEO pay ratio was 62:1

, with CEO Hervé Hoppenot earning $16,659,526 and the median employee compensation at $267,066 .

Fair Trade & Ethical Sourcing

Incyte audits its high-risk suppliers annually, medium-risk suppliers every two years, and low-risk suppliers every three years.

No specific quantitative data was found for fair-trade certified spend, substantiated forced or child labor incidents, supply chain traceability coverage for suppliers, remediation speed for ethical violations, the percentage of contracts with enforceable ethical clauses, the share of spend on high-risk materials, or the percentage of procurement budget directed to diverse suppliers.

Honest & Fair Business

In May 2021, Incyte agreed to pay $12.6 million to resolve allegations of violating the False Claims Act

. These allegations stemmed from the company's use of an independent foundation to pay copays for federal beneficiaries taking their drug Jakafi, which led to false claims to Medicare and TRICARE . The U.S. Department of Justice had issued a civil investigative demand in December 2018 regarding these programs .

Kind to Animals

Incyte's animal care and use program has been accredited by AAALAC International since 2015

and received no suggestions for improvement following its Q4 2024 reaccreditation site visit. The company's animal testing policy commits to ethical and responsible conduct in animal studies, strictly complying with federal, state, and local regulations and performance standards, and encourages employees to continually advance the 3R principles (Replacement, Reduction, and Refinement). However, public disclosures do not indicate specific initiatives aimed at reducing animal testing. Incyte encourages employees to share innovations in research addressing the 3R principles through annual awards. The company is a participant in the VICT3R project, a multi-stakeholder collaboration with 80 partners, which aims to develop virtual control groups to replace approximately 25% of animals used in drug and chemical safety studies and achieve regulatory acceptance for this concept.

Planet-Friendly Business

Incyte achieves 100% waste diversion from landfill for its reported hazardous and non-hazardous waste streams.

The company sources 90% of its operational electricity from renewable sources, including RECs, on-site solar, and utility-provided renewable electricity. Incyte has a target to achieve operational carbon neutrality by 2025 and has already offset 100% of its Scope 1 and 2 emissions from 2019 through 2023. Two of the company's three owned buildings, representing 66.67% of owned facilities, have received Green Globes Certification. Less than 1% of the company's total square footage is situated in areas of high or extremely high baseline water stress. Incyte reports under the TCFD Framework with its third disclosure but plans to enhance its climate risk assessment by incorporating climate scenario analysis, indicating a rudimentary level of analysis. The company's biodiversity efforts include planting 100 trees in local parks in underserved neighborhoods , and it has minimal pilot projects for biodiversity conservation.

Respect for Cultures & Communities

In the late 1990s, Incyte Pharmaceuticals applied for patents on human genes

, an action criticized by indigenous groups as biopiracy due to a lack of informed consent and protection of genetic heritage . The company also supports community engagement through initiatives such as the Incyte Charitable Giving Foundation, which aids nonprofits in Delaware , and the 'Incyte Involved' program, which includes financial donations and volunteer hours . Additionally, Incyte has a Supplier Diversity Program aimed at supporting small and diverse businesses .

Safe & Smart Tech

Incyte has not experienced any reportable cybersecurity breaches in the past three years.

The company achieved 100% completion of mandatory cybersecurity best practices training and refresher modules for employees and contractors in both 2023 and 2024, which included testing via phishing simulation campaigns. A 2025 goal ties executive compensation to employees completing a minimum of two cybersecurity awareness trainings. Incyte is certified to the EU-U.S., UK Extension, and Swiss-U.S. Data Privacy Framework Principles, and its CISO holds numerous cybersecurity certifications, including Certified Information Systems Security Professional. The company states compliance with all applicable privacy and data protection laws, including GDPR and CCPA, and offers opt-out rights via webform or toll-free number. There are no documented incidents of unauthorized data use, and employees are required to access personal information only for appropriate business purposes. However, Incyte collects an extensive range of personal information, including medical, biometric, geolocation, network activity, and inferences, and retains this data for periods described vaguely as "as long as needed or permitted."

Zero Waste & Sustainable Products

Incyte Corporation has achieved landfill-free status for all its owned facilities and 75% of its leased facilities by 2023, demonstrating effective waste diversion.

The company has implemented several waste reduction initiatives, including a 15% reduction in solvent usage per production cycle. This reduction in solvent use also indicates improved material efficiency. Incyte has a quantitative waste reduction target for solvents, committing to and achieving a 15% decrease in usage per production cycle.